1
|
Haspula D, Cui Z. Neurochemical Basis of Inter-Organ Crosstalk in Health and Obesity: Focus on the Hypothalamus and the Brainstem. Cells 2023; 12:1801. [PMID: 37443835 PMCID: PMC10341274 DOI: 10.3390/cells12131801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 06/23/2023] [Accepted: 07/03/2023] [Indexed: 07/15/2023] Open
Abstract
Precise neural regulation is required for maintenance of energy homeostasis. Essential to this are the hypothalamic and brainstem nuclei which are located adjacent and supra-adjacent to the circumventricular organs. They comprise multiple distinct neuronal populations which receive inputs not only from other brain regions, but also from circulating signals such as hormones, nutrients, metabolites and postprandial signals. Hence, they are ideally placed to exert a multi-tier control over metabolism. The neuronal sub-populations present in these key metabolically relevant nuclei regulate various facets of energy balance which includes appetite/satiety control, substrate utilization by peripheral organs and glucose homeostasis. In situations of heightened energy demand or excess, they maintain energy homeostasis by restoring the balance between energy intake and expenditure. While research on the metabolic role of the central nervous system has progressed rapidly, the neural circuitry and molecular mechanisms involved in regulating distinct metabolic functions have only gained traction in the last few decades. The focus of this review is to provide an updated summary of the mechanisms by which the various neuronal subpopulations, mainly located in the hypothalamus and the brainstem, regulate key metabolic functions.
Collapse
Affiliation(s)
- Dhanush Haspula
- Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
| | - Zhenzhong Cui
- Mouse Metabolism Core, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA;
| |
Collapse
|
2
|
Rahman Y, Krisanti RIA, Wisnu W, Sitohang IBS. The Comparison between Free Thyroxine and Thyroid-Stimulating Hormone Levels on Melasma Severity: A Cross-Sectional Study. Open Access Maced J Med Sci 2021. [DOI: 10.3889/oamjms.2021.5952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background: Melasma has been suspected to be linked with levels of thyroid hormone. There is no study that explains the association between thyroid hormone level with melasma severity. Objective: This study aims to find the discrepancies in the levels of thyroid hormone in varying severity of melasma by using two different measurement techniques. Methods: Subjects were chosen consecutively from the dermatology clinic at RSUPN Dr. Cipto Mangunkusomo hospital. Forty-eight patients participated in this study were categorized into mild melasma and moderate-severe melasma based on modified melasma area and severity index (mMASI) and Janus II measurement. Results: Statistically, mMASI measurement showed no significant association between varying melasma severity with levels of thyroid stimulating hormone and free T4 (FT4), P 0.375 and P 0.208, respectively. The Janus II examination using polarized light modality has a weak positive correlation with the serum FT4 level (r=0.3; P 0.039). Weak correlation was also found between the two measurement strategies, Janus II and mMASI (r= 0.314; P 0.03). Conclusion: There are no significant differences observed in levels of thyroid hormone between subjects with varying degrees of melasma severity.
Collapse
|
3
|
Epelbaum J, Terrien J. Mini-review: Aging of the neuroendocrine system: Insights from nonhuman primate models. Prog Neuropsychopharmacol Biol Psychiatry 2020; 100:109854. [PMID: 31891735 DOI: 10.1016/j.pnpbp.2019.109854] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 12/27/2019] [Indexed: 01/29/2023]
Abstract
The neuroendocrine system (NES) plays a crucial role in synchronizing the physiology and behavior of the whole organism in response to environmental constraints. The NES consists of a hypothalamic-pituitary-target organ axis that acts in coordination to regulate growth, reproduction, stress and basal metabolism. The growth (or somatotropic), hypothalamic-pituitary-gonadal (HPG), hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-thyroid (HPT) axes are therefore finely tuned by the hypothalamus through the successive release of hypothalamic and pituitary hormones to control the downstream physiological functions. These functions rely on a complex set of mechanisms requiring tight synchronization between peripheral organs and the hypothalamic-pituitary complex, whose functionality can be altered during aging. Here, we review the results of research on the effects of aging on the NES of nonhuman primate (NHP) species in wild and captive conditions. A focus on the age-related dysregulation of the master circadian pacemaker, which, in turn, alters the synchronization of the NES with the organism environment, is proposed. Finally, practical and ethical considerations of using NHP models to test the effects of nutrition-based or hormonal treatments to combat the deterioration of the NES are discussed.
Collapse
Affiliation(s)
- Jacques Epelbaum
- UMR CNRS/MNHN 7179, Mécanismes Adaptatifs et Evolution, 1 Avenue du Petit Château, 91800 Brunoy, France; Unité Mixte de Recherche en Santé 894 INSERM, Centre de Psychiatrie et Neurosciences, Université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France
| | - Jérémy Terrien
- UMR CNRS/MNHN 7179, Mécanismes Adaptatifs et Evolution, 1 Avenue du Petit Château, 91800 Brunoy, France.
| |
Collapse
|
4
|
Rivera Z, Ollarves V, Rivera I, Hagel I. Clinical factors affecting the efficacy of melasma treatment using the Q-switched 1064 Nd: YAG laser mode in a group of Venezuelan female patients. J COSMET LASER THER 2019; 21:398-403. [PMID: 31658844 DOI: 10.1080/14764172.2019.1680851] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The influence of melasma risk factors on the effectiveness of laser toning treatment in Venezuelan females was investigated. Clinical evaluation was performed (n = 64) including ultrasound and thyroid hormone profile. All patients underwent face exposure with laser toning, eight sessions weekly. VISIA percentiles corresponding to dark brown spots determined before and after treatment were compared by ANOVA. Differences between percentile values before and after treatment for each patient were calculated and expressed as percentages. An improvement of ≥30% was considered as significant. Spearman rank correlations between improvement and clinical parameters were determined. A significant increase (p > .005) of the median of the percentiles in the overall group was observed. However, only 62.5% of the patients exhibited an improvement of ≥30% at the right malar, 73.4% at the frontal and 71.8% at the left malar areas. Hormonal contraception during treatment (right malar: p < .0001 left malar: p = .0035), thyroid disorders (right malar: p < .0001; frontal: p = .011; left malar: p < .0001) and photoaging (right malar: p = .0235; frontal: p = .0237; left malar: p = .0137) were inversely associated to melasma improvement after treatment. Prolonged use of sunscreen improved significantly (right malar: p < .001; frontal: p = .016 and left malar: p = .025) treatment effectiveness.
Collapse
Affiliation(s)
- Zulay Rivera
- Sección de Investigación, Unidad Médico Estética Láser UNIMEL, Caracas, Venezuela.,Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela
| | - Victor Ollarves
- Sección de Investigación, Unidad Médico Estética Láser UNIMEL, Caracas, Venezuela
| | - Ingrid Rivera
- Sección de Investigación, Unidad Médico Estética Láser UNIMEL, Caracas, Venezuela.,Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela
| | - Isabel Hagel
- Sección de Investigación, Unidad Médico Estética Láser UNIMEL, Caracas, Venezuela.,Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela
| |
Collapse
|
5
|
Etiopathogenetic factors, thyroid functions and thyroid autoimmunity in melasma patients. Postepy Dermatol Alergol 2016; 32:327-30. [PMID: 26759539 PMCID: PMC4692817 DOI: 10.5114/pdia.2015.54742] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Accepted: 01/13/2015] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION Melasma is a common chronic, acquired pigmentation disorder with a significant impact on the quality of life of patients. AIM To investigate the etiopathogenetic factors, thyroid functions and thyroid autoimmunity in patients with melasma. MATERIAL AND METHODS Forty-five women with melasma and 45 age-matched healthy women were included in the study group. A detailed history was taken from the patients including triggering factors of melasma. Serum free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin (AbTG) and anti-thyroid peroxidase (Ab-TPO) were measured and thyroid ultrasonography was performed for each subject. RESULTS In 26.7% of patients, pregnancy, in 17.8%, oral contraceptive use and in 13.3%, intense sunlight exposure were the triggering factors. 17.8% of patients had a family history of melasma. FT4, TSH and AbTG levels were significantly higher in the patient group. CONCLUSIONS The results suggest that a combination of factors including pregnancy, oral contraceptive use, sunlight and genetic factors often trigger melasma. Thyroid hormones and thyroid autoimmunity may also play a role in the pathogenesis which needs to be proven by further studies.
Collapse
|
6
|
Derkach KV, Moiseyuk IV, Shpakova EA, Shpakov AO. The thyroid status of rats immunized with peptides derived from the extracellular regions of the types 3 and 4 melanocortin receptors and the 1B-subtype 5-hydroxytryptamine receptor. J EVOL BIOCHEM PHYS+ 2015. [DOI: 10.1134/s0022093015040031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
7
|
Bantubungi K, Prawitt J, Staels B. Control of metabolism by nutrient-regulated nuclear receptors acting in the brain. J Steroid Biochem Mol Biol 2012; 130:126-37. [PMID: 22033286 DOI: 10.1016/j.jsbmb.2011.10.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2011] [Revised: 10/04/2011] [Accepted: 10/08/2011] [Indexed: 12/22/2022]
Abstract
Today, we are witnessing a rising incidence of obesity worldwide. This increase is due to a sedentary life style, an increased caloric intake and a decrease in physical activity. Obesity contributes to the appearance of type 2 diabetes, dyslipidemia and cardiovascular complications due to atherosclerosis, and nephropathy. Therefore, the development of new therapeutic strategies may become a necessity. Given the metabolism controlling properties of nuclear receptors in peripheral organs (such as liver, adipose tissues, pancreas) and their implication in various processes underlying metabolic diseases, they constitute interesting therapeutic targets for obesity, dyslipidemia, cardiovascular disease and type 2 diabetes. The recent identification of the central nervous system as a player in the control of peripheral metabolism opens new avenues to our understanding of the pathophysiology of obesity and type 2 diabetes and potential novel ways to treat these diseases. While the metabolic functions of nuclear receptors in peripheral organs have been extensively investigated, little is known about their functions in the brain, in particular with respect to brain control of energy homeostasis. This review provides an overview of the relationships between nuclear receptors in the brain, mainly at the hypothalamic level, and the central regulation of energy homeostasis. In this context, we will particularly focus on the role of PPARα, PPARγ, LXR and Rev-erbα.
Collapse
Affiliation(s)
- Kadiombo Bantubungi
- Univ Lille Nord de France, INSERM UMR1011, UDSL, Institut Pasteur de Lille, Lille, France
| | | | | |
Collapse
|
8
|
Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2011; 2:163-174. [PMID: 21966642 PMCID: PMC3177041 DOI: 10.1007/s13539-011-0039-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 08/16/2011] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND: Under physiological conditions, the melanocortin system is a crucial part of the complex network regulating food intake and energy expenditure. In pathological states, like cachexia, these two parameters are deregulated, i.e., food intake is decreased and energy expenditure is increased-a vicious combination leading to catabolism. Agouti-related protein (AgRP), the endogenous antagonist at the melanocortin-4 receptor (MC-4R), was found to increase food intake and to reduce energy expenditure. This qualifies MC-4R blockade as an attractive mode of action for the treatment of cachexia. Based on this rationale, a novel series of small-molecule MC-4R antagonists was designed, from which the orally active compound BL-6020/979 (formerly known as SNT207979) emerged as the first promising development candidate showing encouraging pre-clinical efficacy and safety properties which are presented here. METHODS AND RESULTS: BL-6020/979 is an orally available, selective and potent MC-4R antagonist with a drug-like profile. It increased food intake and decreased energy expenditure in healthy wild-type but not in MC-4R deficient mice. More importantly, it ameliorated cachexia-like symptoms in the murine C26 adenocarcinoma model; with an effect on body mass and body composition and on the expression of catabolic genes. Moreover, BL-6020/979 showed antidepressant-like properties in the chronic mild stress model in rats and exhibits a favorable safety profile. CONCLUSION: The properties of BL-6020/979 demonstrated in animal models and presented here make it a promising candidate suitable for further development towards a first-in-class treatment option for cachexia that potentially opens up the opportunity to treat two hallmarks of the disease, i.e., decreased food intake and increased energy expenditure, with one drug.
Collapse
Affiliation(s)
- R. Dallmann
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
- Institute of Pharmacology and Toxicology; University of Zurich; Winterthurerstr. 190 8057 Zurich
| | - P. Weyermann
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - C. Anklin
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Boroff
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - K. Bray-French
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - B. Cardel
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - I. Courdier-Fruh
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Deppe
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - J. Dubach-Powell
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Erb
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - R. H. Haefeli
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Henneböhle
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Herzner
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Hufschmid
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - D. L. Marks
- Department of Pediatric Endocrinology, Vollum Institute; Oregon Health Sciences University; Portland
| | - S. Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Papp
- Institute of Pharmacology; Polish Academy of Sciences; Krakow
| | - C. Rummey
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - G. Santos
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - F. Schärer
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Siendt
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Soeberdt
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - L. T. Sumanovski
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Terinek
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - C. Mondadori
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - N. Güven
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - A. Feurer
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| |
Collapse
|
9
|
Abstract
Precise automatic control of food intake and energy expenditure maintains a steady weight and is fundamental to survival. The brainstem and hypothalamus are key areas within the brain that integrate peripheral signals from the gut and adipose tissue to control feeding behavior according to energy need. Gut hormones are released after a meal and signal to the brain to initiate meal termination and feelings of satiation. However, reward pathways are able to override this mechanism so that when palatable food is presented, food is consumed irrespective of energy requirements.
Collapse
Affiliation(s)
- Katherine A Simpson
- Section of Investigative Medicine, Imperial College London, Commonwealth Building, Du Cane Road, London, W12 0NN, UK
| | | |
Collapse
|
10
|
Lampert KP, Schmidt C, Fischer P, Volff JN, Hoffmann C, Muck J, Lohse MJ, Ryan MJ, Schartl M. Determination of onset of sexual maturation and mating behavior by melanocortin receptor 4 polymorphisms. Curr Biol 2010; 20:1729-34. [PMID: 20869245 DOI: 10.1016/j.cub.2010.08.029] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2010] [Revised: 07/16/2010] [Accepted: 08/13/2010] [Indexed: 11/30/2022]
Abstract
Polymorphisms in reproductive strategies are among the most extreme and complex in nature. A prominent example is male body size and the correlated reproductive strategies in some species of platyfish and swordtails of the genus Xiphophorus. This polymorphism is controlled by a single Mendelian locus (P) that determines the onset of sexual maturity of males. Because males cease growth after reaching puberty, this results in a marked size polymorphism. The different male size classes show pronounced behavioral differences (e.g., courtship versus sneak mating), and females prefer large over small males. We show that sequence polymorphisms of the melanocortin receptor 4 gene (mc4r) comprise both functional and non-signal-transducing versions and that variation in copy number of mc4r genes on the Y chromosome underlies the P locus polymorphism. Nonfunctional Y-linked mc4r copies in larger males act as dominant-negative mutations and delay the onset of puberty. Copy number variation, as a regulating mechanism, endows this system with extreme genetic flexibility that generates extreme variation in phenotype. Because Mc4r is critically involved in regulation of body weight and appetite, a novel link between the physiological system controlling energy balance and the regulation of reproduction becomes apparent.
Collapse
Affiliation(s)
- Kathrin P Lampert
- Physiological Chemistry I, Biocenter, University of Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Simpson KA, Martin NM, Bloom SR. Hypothalamic regulation of food intake and clinical therapeutic applications. ACTA ACUST UNITED AC 2010; 53:120-8. [PMID: 19466203 DOI: 10.1590/s0004-27302009000200002] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2009] [Accepted: 02/15/2009] [Indexed: 02/07/2023]
Abstract
Current estimates suggest that over 1 billion people are overweight and over 300 million people are obese. Weight gain is due to an imbalance between energy expenditure and dietary intake. This review discusses the hypothalamic control of appetite and highlights key developments in research that have furthered our understanding of the complex pathways involved. Nuclei within the hypothalamus integrate peripheral signals such as adiposity and caloric intake to regulate important pathways within the central nervous system controlling food intake and energy expenditure. Firmly established pathways involve the orexigenic NPY/AgRP and the anorexigenic POMC/CART neurons in the arcuate nucleus (ARC) of the hypothalamus. These project from the ARC to other important hypothalamic nuclei, including the paraventricular, dorsomedial, ventromedial and lateral hypothalamic nuclei. In addition there are many projections to and from the brainstem, cortical areas and reward pathways, which modulate food intake.
Collapse
|
12
|
Prior LJ, Armitage JA. Neonatal overfeeding leads to developmental programming of adult obesity: you are what you ate. J Physiol 2009; 587:2419. [PMID: 19483248 DOI: 10.1113/jphysiol.2009.174045] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
- L J Prior
- Baker IDI Heart and Diabetes Institute, Monash University, Clayton, Victoria, Australia
| | | |
Collapse
|
13
|
Müller TD, Föcker M, Holtkamp K, Herpertz-Dahlmann B, Hebebrand J. Leptin-mediated neuroendocrine alterations in anorexia nervosa: somatic and behavioral implications. Child Adolesc Psychiatr Clin N Am 2009; 18:117-29. [PMID: 19014861 DOI: 10.1016/j.chc.2008.07.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Hypoleptinemia is a key endocrinological feature of anorexia nervosa (AN). Several symptoms in acute AN are related to the low circulating leptin levels including amenorrhea and semi-starvation-induced hyperactivity. The drop in leptin levels results from the loss of fat mass; once leptin levels fall below specific thresholds the hypothalamic-pituitary-gonadal and -thyroid axes are down-regulated; in contrast, the hypothalamic-pituitary-adrenal axis is up-regulated. Hypoleptinemia is the major signal underlying both somatic and behavioral adaptations to starvation. Because the mechanisms involved in this adaptation are similar in rodents and humans, rodent models can be used to investigate the relevant central pathways which underly the respective starvation-induced symptoms. During therapeutically induced weight gain, leptin levels can intermittently increase above normal concentrations. This hyperleptinemia could predispose to renewed weight loss.
Collapse
Affiliation(s)
- Timo D Müller
- Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Virchowstrasse 174, 45147 Essen, Germany
| | | | | | | | | |
Collapse
|
14
|
Abstract
The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research has focused on trying to understand the complex pathways involved in controlling these aspects. This review highlights the key areas of research in the hypothalamic control of appetite. The hypothalamus consists of several nuclei that integrate peripheral signals, such as adiposity and caloric intake, to regulate important pathways within the CNS controlling food intake. The best characterized pathways are the orexigenic neuropeptide Y/Agouti-related protein and the anorexigenic pro-opiomelanocortin/cocaine- and amphetamine-related transcript neurons in the arcuate nucleus of the hypothalamus. These project from the arcuate nucleus to other key hypothalamic nuclei, such as the paraventricular, dorsomedial, ventromedial and lateral hypothalamic nuclei. There are also projections to and from the brainstem, cortical areas and reward pathways, all of which influence food intake. The challenge at present is to understand the complexity of these pathways and try to find ways of modulating them in order to find potential therapeutic targets.
Collapse
Affiliation(s)
- Katherine A Simpson
- a Department of Investigative Medicine, Imperial College, London W12 ONN, UK
| | - Niamh M Martin
- a Department of Investigative Medicine, Imperial College, London W12 ONN, UK
| | - Steve R Bloom
- b Department of Investigative Medicine, Imperial College, London W12 ONN, UK.
| |
Collapse
|
15
|
Price CJ, Hoyda TD, Samson WK, Ferguson AV. Nesfatin-1 influences the excitability of paraventricular nucleus neurones. J Neuroendocrinol 2008; 20:245-50. [PMID: 18088358 DOI: 10.1111/j.1365-2826.2007.01641.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Nesfatin-1 is a newly-discovered satiety peptide found in several nuclei of the hypothalamus, including the paraventricular nucleus. To begin to understand the physiological mechanisms underlying these satiety-inducing actions, we examined the effects of nesfatin-1 on the excitability of neurones in the paraventricular nucleus. Whole-cell current-clamp recordings from rat paraventricular nucleus neurones showed nesfatin-1 to have either hyperpolarizing or depolarising effects on the majority of neurones tested. Both types of response were observed in neurones irrespective of classification based on electrophysiological fingerprint (magnocellular, neuroendocrine or pre-autonomic) or molecular phenotype (vasopressin, oxytocin, corticotrophin-releasing hormone, thyrotrophin-releasing hormone or vesicular glutamate transporter), determined using single cell reverse transcription-polymerase chain reaction. Consequently, we provide the first evidence that this peptide, which is produced in the paraventricular nucleus, has effects on the membrane potential of a large proportion of different subpopulations of neurones located in this nucleus, and therefore identify nesfatin-1 as a potentially important regulator of paraventricular nucleus output.
Collapse
Affiliation(s)
- C J Price
- Department of Physiology, Queen's University, Kingston, Ontario, Canada
| | | | | | | |
Collapse
|
16
|
Tachibana T, Oikawa D, Adachi N, Boswell T, Furuse M. Central administration of alpha-melanocyte-stimulating hormone changes lipid metabolism in chicks. Comp Biochem Physiol A Mol Integr Physiol 2007; 148:408-12. [PMID: 17600745 DOI: 10.1016/j.cbpa.2007.05.023] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2006] [Revised: 05/31/2007] [Accepted: 05/31/2007] [Indexed: 11/27/2022]
Abstract
Alpha-melanocyte-stimulating hormone (MSH) is well known as an anorexigenic peptide in the brain of mammals. In addition to this, brain alpha-MSH enhances heat production (HP), indicating that the peptide acts as a catabolic factor in the regulation of energy metabolism. The anorexigenic effect of alpha-MSH is also observed in chicks (Gallus gallus), but no information has been available for its effect on HP. The present study was performed to examine whether intracerebroventricular (ICV) injection of alpha-MSH increases HP in chicks. The injection of alpha-MSH (10 and 100 pmol) did not affect oxygen consumption, carbon dioxide production and HP during the 1 h post-injection period. This result was supported by another result that ICV injection of alpha-MSH did not affect locomotion activity in chicks. In contrast, the respiratory quotient was significantly lowered by the ICV injection of MSH. We also found that alpha-MSH significantly increased plasma non-esterified fatty acid concentrations. In summary, brain alpha-MSH appears to exert generally catabolic effects on lipid metabolism in the chick, but does not appear to be involved in the regulation of HP.
Collapse
Affiliation(s)
- Tetsuya Tachibana
- Laboratory of Advanced Animal and Marine Bioresources, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka 812-8581, Japan.
| | | | | | | | | |
Collapse
|
17
|
Lee M, Kim A, Chua SC, Obici S, Wardlaw SL. Transgenic MSH overexpression attenuates the metabolic effects of a high-fat diet. Am J Physiol Endocrinol Metab 2007; 293:E121-31. [PMID: 17374695 DOI: 10.1152/ajpendo.00555.2006] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To determine whether long-term melanocortinergic activation can attenuate the metabolic effects of a high fat diet, mice overexpressing an NH(2)-terminal POMC transgene that includes alpha- and gamma(3)-MSH were studied on either a 10% low-fat diet (LFD) or 45% high-fat diet (HFD). Weight gain was modestly reduced in transgenic (Tg-MSH) male and female mice vs. wild type (WT) on HFD (P < 0.05) but not LFD. Substantial reductions in body fat percentage were found in both male and female Tg-MSH mice on LFD (P < 0.05) and were more pronounced on HFD (P < 0.001). These changes occurred in the absence of significant feeding differences in most groups, consistent with effects of Tg-MSH on energy expenditure and partitioning. This is supported by indirect calorimetry studies demonstrating higher resting oxygen consumption and lower RQ in Tg-MSH mice on the HFD. Tg-MSH mice had lower fasting insulin levels and improved glucose tolerance on both diets. Histological and biochemical analyses revealed that hepatic fat accumulation was markedly reduced in Tg-MSH mice on the HFD. Tg-MSH also attenuated the increase in corticosterone induced by the HFD. Higher levels of Agrp mRNA, which might counteract effects of the transgene, were measured in Tg-MSH mice on LFD (P = 0.02) but not HFD. These data show that long-term melanocortin activation reduces body weight, adiposity, and hepatic fat accumulation and improves glucose metabolism, particularly in the setting of diet-induced obesity. Our results suggest that long-term melanocortinergic activation could serve as a potential strategy for the treatment of obesity and its deleterious metabolic consequences.
Collapse
Affiliation(s)
- Michelle Lee
- Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th St., New York, NY 10032, USA
| | | | | | | | | |
Collapse
|
18
|
Pogoda HM, Hammerschmidt M. Molecular genetics of pituitary development in zebrafish. Semin Cell Dev Biol 2007; 18:543-58. [PMID: 17560816 DOI: 10.1016/j.semcdb.2007.04.004] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Accepted: 04/10/2007] [Indexed: 11/21/2022]
Abstract
The pituitary gland of vertebrates consists of two major parts, the neurohypophysis (NH) and the adenohypophysis (AH). As a central part of the hypothalamo-hypophyseal system (HHS), it constitutes a functional link between the nervous and the endocrine system to regulate basic body functions, such as growth, metabolism and reproduction. The development of the AH has been intensively studied in mouse, serving as a model for organogenesis and differential cell specification. However, given that the AH is a relatively recent evolutionary advance of the chordate phylum, it is also interesting to understand its development in lower chordate systems. In recent years, the zebrafish has emerged as a powerful lower vertebrate system for developmental studies, being amenable for large-scale genetic approaches, embryological manipulations, and in vivo imaging. Here, we present an overview of current knowledge of the mechanisms and genetic control of pituitary formation during zebrafish development. First, we describe the components of the zebrafish HHS, and the different pituitary cell types and hormones, followed by a description of the different steps of normal pituitary development. The central part of the review deals with the genes found to be essential for zebrafish AH development, accompanied by a description of the corresponding mutant phenotypes. Finally, we discuss future directions, with particular focus on evolutionary aspects, and some novel functional aspects with growing medical and social relevance.
Collapse
Affiliation(s)
- Hans-Martin Pogoda
- Max-Planck Institute of Immunobiology, Stübeweg 51, D-79108 Freiburg, Germany
| | | |
Collapse
|
19
|
Bibliography. Current world literature. Growth and development. Curr Opin Endocrinol Diabetes Obes 2007; 14:74-89. [PMID: 17940424 DOI: 10.1097/med.0b013e32802e6d87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Singru PS, Sánchez E, Fekete C, Lechan RM. Importance of melanocortin signaling in refeeding-induced neuronal activation and satiety. Endocrinology 2007; 148:638-46. [PMID: 17068131 DOI: 10.1210/en.2006-1233] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
To identify regions in the hypothalamus involved in refeeding and their regulation by alpha-MSH, adult rats were subjected to a 3-d fast, and 2 h after refeeding, the distribution of c-Fos-immunoreactive neurons was elucidated. Compared with fed and fasted animals, a significant increase (P < 0.001) in the number of c-Fos-immunoreactive cells was identified in refed animals in the supraoptic nucleus, magnocellular and ventral parvocellular subdivisions of the hypothalamic paraventricular nucleus (PVNv), and the dorsal and ventral subdivisions of the dorsomedial nucleus (DMNd and DMNv, respectively). Refeeding shifted the location of c-Fos-labeled neurons from the medial to lateral arcuate where c-Fos was induced in 88.7 +/- 2.2% of alpha-MSH-containing neurons. alpha-MSH-containing axons densely innervated the PVNv, DMNd, and DMNv and organized in close apposition to the majority of refeeding-activated c-Fos-positive neurons. To test whether the melanocortin system is involved in induction of c-Fos in these regions, the melanocortin 3/4 receptor antagonist, agouti-related protein (AGRP 83-132), was administered to fasting animals just before refeeding. Compared with artificial cerebrospinal fluid, a single intracerebroventricular bolus of agouti-related protein (5 microg/5 microl) not only significantly increased the total amount of food consumed within 2 h but also nearly abolished refeeding-induced c-Fos expression in the PVNv and DMNd and partially reduced c-Fos immunoreactivity in the DMNv. We conclude that refeeding activates a subset of neurons in the PVN and DMN as a result of increased melanocortin signaling and propose that one or more of these neuronal populations mediate the potent anorexic actions of alpha-MSH.
Collapse
Affiliation(s)
- Praful S Singru
- Professor of Medicine, Division of Endocrinology, Box No. 268, New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111, USA
| | | | | | | |
Collapse
|
21
|
Abstract
PURPOSE OF REVIEW In the USA, 8-10 million people are morbidly obese, which is associated with a high frequency of comorbidities. The most effective treatment is surgery. Of around 180,000 bariatric operations performed in 2005, 80% were Roux-en-Y gastric bypass, consisting of a small gastric pouch to minimize food intake and a Roux-en-Y of distal small bowel bypassing the upper gastrointestinal tract. The precise mechanisms whereby Roux-en-Y gastric bypass achieves sustained weight loss remain unknown. To gain insight into the catabolic events of sustained weight loss we developed a diet-induced obese Roux-en-Y gastric bypass rat model. We review our rat model data from the novel viewpoint of the catabolic state, comparing it with the limited human data available and the catabolic events occurring in cancer anorexia/cachexia syndrome. RECENT FINDINGS Current data suggest the involvement of mechanisms other than restrictive and malabsorptive factors of the Roux-en-Y gastric bypass, classically thought of as the mechanisms responsible for weight loss. Based on available data, gastrointestinal hormones and cytokines play a key role in reducing food intake and regulating energy homeostasis. Because of the cross talk between peripheral modulators and the hypothalamus, a critical role for their interaction in the outcome of Roux-en-Y gastric bypass is emerging. SUMMARY In our Roux-en-Y gastric bypass rat model many of the changes in gastrointestinal hormones, adipokines and cytokines as well as in hypothalamic neuropeptides and neurotransmitters resemble the changes observed in the anorexia/cachexia rat model, suggesting that Roux-en-Y gastric bypass triggers a catabolic state responsible for loss of appetite and prolonged body weight reduction.
Collapse
Affiliation(s)
- Ana Guijarro
- Surgical Metabolism and Nutrition Laboratory, Department of Surgery, SUNY Upstate Medical University, Syracuse, New York 13021, USA
| | | | | |
Collapse
|